PSMAI cut-off value for mortality in men: 680.1 mm2/m2

ASCO GU 2022: Predicting the Outcome of mCPRC Patients after Lu-177 PSMA Therapy Using Semi-Quantitative and Visual Criteria in Baseline PSMA PET: An International Multicenter Retrospective Study

Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study - ScienceDirect

EAU 2023: LuTectomy: A Prospective Study of Dosimetry, Safety and Potential Benefit of Upfront 177Lu-PSMA-617 Radioligand Therapy Prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer

Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies

Abstract 11678: ST2 Is A Biomarker Of Pediatric Pulmonary Arterial Hypertension Severity And Clinical Worsening

Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies

The forest plots, Galbraith plot, sensitivity analysis, and subgroup

Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients

Yusuf BAĞ, Medical Doctor, Inonu University, Malatya, Department of General Surgery

Computed tomographic images at the the middle third lumbar vertebral